Wird geladen...
Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial
PURPOSE: Recent data suggest that the glutamatergic system is important in the proliferation and migration of glioblastoma. Talampanel is a well-tolerated, oral α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor blocker that could be beneficial in this disease. PATIENTS AND METHODS...
Gespeichert in:
Hauptverfasser: | , , , , , , , , |
---|---|
Format: | Artigo |
Sprache: | Inglês |
Veröffentlicht: |
American Society of Clinical Oncology
2009
|
Schlagworte: | |
Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2734427/ https://ncbi.nlm.nih.gov/pubmed/19636006 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.21.6895 |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|